MINI REVIEW article
Front. Med.
Sec. Gene and Cell Therapy
Volume 12 - 2025 | doi: 10.3389/fmed.2025.1591287
This article is part of the Research TopicWomen in Science – Gene and Cell Therapy 2024View all articles
CELL THERAPY IN PEDIATRIC BLOOD DISEASES
Provisionally accepted
- 1Secretaría de Ciencia, Humanidades, Tecnología e Innovación, Ciudad de Mexico, Mexico
- 2Laboratorio de Citómica del Cáncer Infantil, Centro de Investigación Biomédica de Oriente, IMSS OOAD Puebla, Puebla, Mexico
- 3Unidad de Educación e Investigación, Mexican Social Security Institute, Mexico City, México, Mexico
- 4Biomedical Research Center of East (CIBIOR), Puebla, Mexico
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
The fight against mortality in pediatric oncohematological diseases is a story of human rights, academia, innovation, and technological advancement-one in which women in science have played a pivotal role. With talent, perseverance, and sensitivity, they greatly contributed to research in new cellular therapies, expanding the frontiers of treatment and giving the most vulnerable patients the gift of more years of life. This review explores multipotent and unipotent cell therapies, focusing on hematopoietic stem cell transplantation (HSCT), mesenchymal stromal cell transplantation (MSCT), and chimeric antigen receptor (CAR)-T cell and natural killer (NK) cell therapy. HSCT remains the gold standard for high-risk and relapsed cases, with graft sources including bone marrow (BM), mobilized peripheral blood (MPB), and umbilical cord blood (UCB). Advances in MSCT highlight its role in hematopoiesis support and immunomodulation, reducing graft-versushost disease (GVHD) risks. CAR-T cell therapy has revolutionized leukemia treatment, although challenges such as antigen escape, T-cell exhaustion, and treatment resistance persist. Emerging strategies, including CAR-NK cells, seek to enhance efficacy while minimizing toxicity. Despite these advancements, cell therapy remains complex and resource-intensive, necessitating further innovations for broader accessibility, particularly in developing regions.
Keywords: Pediatric hematological diseases, HSC trasplantation, MSC trasplantation, CAR-T cells, CAR-NK cells
Received: 10 Mar 2025; Accepted: 06 Jun 2025.
Copyright: © 2025 Romo-Rodríguez, Pelayo and Ramírez-Ramírez. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Dalia Ramírez-Ramírez, Biomedical Research Center of East (CIBIOR), Puebla, Mexico
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.